Early Data Support Neoadjuvant Immunotherapy for NSCLC Early Data Support Neoadjuvant Immunotherapy for NSCLC
A handful of studies on neoadjuvant immunotherapy for lung cancer are nearing completion, Mark Kris reports.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
More News: Cancer | Cancer & Oncology | Health | Hematology | Immunotherapy | Lung Cancer | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Study